Ropes & Gray represented Arbor Biotechnologies in its $73.9 million Series C financing to support the advancement of its novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). The financing was announced in a March 18 press release.
Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, Mass.
The team was led by venture capital and emerging companies partner Brad Flint.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.